<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810702</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0531</org_study_id>
    <nct_id>NCT04810702</nct_id>
  </id_info>
  <brief_title>Impact of Von Willebrand Factor and Its Multimers on Angiogenesis</brief_title>
  <acronym>WILLANGIO</acronym>
  <official_title>Impact of Von Willebrand Factor and Its Multimers on Angiogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to study the expression of numerous proteins involved in angiogenesis in 70&#xD;
      patients with von Willebrand disease in order to try to identify markers of interest.&#xD;
      Secondly, the investigators plan to investigate whether there is a relationship between the&#xD;
      proteins tested, the distribution of multimers and the clinical phenotype of the patients, in&#xD;
      particular by looking for the presence of bleeding linked to the presence of angiodysplasias.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the distribution of multimers assays between different groups of patients and the control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the distribution of protein assays between different groups of patients and the control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the relationship between the distribution of multimers and the clinical phenotype of patients, and in particular the presence of angiodysplasias</measure>
    <time_frame>1 year</time_frame>
    <description>To study the correlation between the clinical phenotype and the assays of angiogenesis proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the relationship between the markers of interest and the clinical phenotype of patients, and in particular the presence of angiodysplasias</measure>
    <time_frame>1 year</time_frame>
    <description>To study the correlation between the clinical phenotype and the distribution of multimers</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Von Willebrand Diseases</condition>
  <arm_group>
    <arm_group_label>patients with von Willebrand disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>case control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>case control</arm_group_label>
    <arm_group_label>patients with von Willebrand disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      frozen plasma fractions&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The studied population will be composed of:&#xD;
&#xD;
          -  70 patients with von Willebrand disease: 10 type 1 patients, 10 type 2A (IIA)&#xD;
             patients, 10 type 2A (IIE) patients, 10 type 2B patients, 10 type 2M patients, 10 type&#xD;
             2M patients (2A-like) and 10 type 3 patients.&#xD;
&#xD;
          -  20 healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For patients:&#xD;
&#xD;
          -  Patient with von Willebrand disease proven by genetic analysis of the VWF gene.&#xD;
&#xD;
          -  Lack of treatment that could interfere with angiogenesis.&#xD;
&#xD;
          -  Patient informed by an information note sent to his home, with the possibility of&#xD;
             objecting to the use of his blood samples in the context of research.&#xD;
&#xD;
        For the control:&#xD;
&#xD;
          -  Patient with a normal coagulation report&#xD;
&#xD;
          -  Absence of abnormal hemorrhagic symptoms&#xD;
&#xD;
          -  Lack of notion of angiodysplasia.&#xD;
&#xD;
          -  Lack of treatment that could interfere with angiogenesis.&#xD;
&#xD;
          -  Patient informed by an information note sent to his home, with the possibility of&#xD;
             objecting to the use of his blood samples in the context of research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship or curatorship.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Blood transfusion or treatment with von Willebrand factor concentrates less than 7&#xD;
             days old.&#xD;
&#xD;
          -  Treatment which may interfere with angiogenesis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Fouassier</last_name>
      <phone>0240084049</phone>
      <email>marc.fouassier@chu-nantes.fr)</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

